Development of innovative nucleic acid medicine for gastroenterological cancer

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K15615
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Digestive surgery
• Research Institution: Osaka University
• Principal Investigator: KONNO Masamitsu 大阪大学, 医学系研究科, 寄附講座講師 (80618207)
• Co-Investigator(Kenkyū-buntansha): 石井 秀始 大阪大学, 医学系研究科, 特任教授(常勤) (10280736) ; 川本 弘一 大阪大学, 医学部附属病院, その他 (30432470) ; 西田 尚弘 大阪大学, 医学系研究科, 助教 (50588118) ; 小関 準 大阪大学, 医学系研究科, 特任助教(常勤) (20616669)
• Co-Investigator(Renkei-kenkyūsha): OBIKA Satoshi 大阪大学, 大学院薬学系研究科, 教授 (80243252) ; NISHIYAMA Nobuhiro 東京工業大学, 化学生命科学研究所, 教授 (10372385) ; MORI Masaki 大阪大学, 大学院医学系研究科, 教授 (70190999)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: 癌 / 核酸 / 創薬

Outline of Final Research Achievements

We designed 20 kinds of guide chain and a passenger chain based on natural sequence of miR302 or miR200c. 400 kinds of artificial nucleic acid medicine were elaborated. The arrangement expected that a RNase in the body could be endured based on the former experience was designed. A screening was performed and even about 3 kinds of the artificial building type miR302, 200c was narrowed down respectively. These nucleic acids were injected to natural pancreatic cancer and a colon cancer carcinogenic model mouse. The volume of the cancer was measured and a presence of adverse event was monitored. Finally we identified the most efficient artificial building type nucleic acid medicine.

Free Research Field

腫瘍生物学